The EquipEX LIGAN-Personalized Medicine genomic center, headed by Professor Philippe FROGUEL and Doctor Amélie Bonnefond, is mainly dedicated to the analysis of the human genome and its abnormalities. Its latest generation high-throughput sequencers allow the sequencing of the genome of patients suffering from frequent or rare diseases (responsible for diabetes, obesity, cardiovascular disease, cancer, kidney disease).
LIGAN-PM’s teams of molecular biologists, computer scientists and bioinformaticians diagnose genetic diseases (under COFRAC ISO 15189 accreditation) and identify new genes for frequent or rare diseases. This European accreditation makes it possible to make genetic diagnoses as a Laboratory of Medical Biology.
LIGAN-PM provides medical research with the most efficient methodologies and protocols for the genomic and multiomic analysis of human diseases.
The LIGAN-PM platform also aims to provide very high-level training at different qualification levels (technicians, engineers, thesis students, post-docs).
LIGAN-PM plays a driving role in numerous scientific projects within the framework of public and private partnerships and offers genomic services of exceptional quality at reduced costs.
Website : http://ligan.good.cnrs.fr/
Contact : http://ligan.good.cnrs.fr/informations-pratiques/contact/
DiabInnov is a research platform that assists companies and academia in the discovery and development of innovative therapies for the treatment of metabolic diseases and their comorbidities to provide a significant advance in patient care.
It consists of a translational and multidisciplinary research team, setting the standard for preclinical studies in human islets and unique animal models, and clinical studies in humans.
Its mission is to place fundamental, preclinical and clinical research in metabolism at the service of life science companies, and academia enabling discovering of new pharmacological targets, testing novel compounds and accelerating safety and efficacy testing of innovative medical devices.
The main researches area of DiabInnov is focused on human metabolism, focusing on islet isolation for clinical transplantation and translational research, complemented by fundamental research on human islet cell biology.
Our research platform aims also the identification and validation of new molecular biomarkers associated with obesity and its comorbidities, in particular type 2 diabetes, through the unique human islet cohort from lean, obese, and diabetic donors and the ABOS biobank: a translational research collection of metabolic tissues (liver, muscle, visceral and subcutaneous adipose tissue, intestine) and blood samples (plasma, serum, DNA) from > 1600 obese who underwent bariatric surgery. DiabInnov perspective is to promote dialogue between scientists, researchers and surgeons on one side, and pharmaceutical companies and innovative medical device manufacturers on the other.
This biomedical gateway to biotechnological innovation facilitates the obtaining of patents, the acceleration of CE marking, the implementation of new surgical approaches and a know-how of excellence.
Website : https://diabinnov.eu/
Contact : firstname.lastname@example.org
EGID INNOVATION Plateform
The “EGID Innovation” platform is a project hotel. Located in the heart of the EGID building, it is intended to house biotechnology companies that are developing their projects in synergy with EGID. It complements the services offered by hotels with traditional projects by providing access to an exceptional scientific environment (Labex), state-of-the-art equipment and technological platforms of excellence (Equipex).
Services and Benefits
Hosting of Spin-offs from research laboratories, joint laboratories and innovative Sartups, with all the following advantages :
- benefit of the entire infrastructure and its maintenance,
- diversified agenda of events and proximity promoting interactions and the exchange of good practices between researchers and entrepreneurs.
Advice and assistance to project leaders in the critical phases of maturation, creation and development:
- saving time-consuming procedures (eg permits for handling radioactivity or biological material, etc.);
- connection with CROs (Contract Research Organizations) according to the needs of startups;
- opening up to a rich and diverse network of service and event providers within EGID.
To ensure its proper functioning, EGID Innovation relies on the promotion unit and its network of partners.
Contact : page Contact Us
Plateau d’Immunophénotypage Métabolique Plateform
An ever-increasing number of studies illustrate the very important role played by cells of the immune system in cardiometabolic pathologies and their complications. In addition, the metabolic status of an individual partly conditions the state of his immune system. In both cases, the detailed characterization of the immune system represents an important element in the diagnosis and in the understanding of the physiopathological mechanisms.
That’s why within the framework of EGID-Labex, we have developed an original strategy for a metabolic immunophenotyping platform for analyzes in humans and in experimental or preclinical models.
This platform aims at the parallel analysis of metabolic parameters and cells and immune functions. To this end, strategies for the simultaneous analysis by flow cytometry of a large number of markers (up to 18 fluorescence parameters) have been developed not only for blood cells but also for adipose tissue, liver, muscle, intestine and skin. At the same time, we are developing strategies for analyzing endocrine cells, particularly in the pancreas. Cell sorting can also be carried out in order to purify the cell populations of interest for functional and / or molecular analyzes.
The immuno-phenotyping platform is equipped with several advanced equipment : a sorting analyzer allowing the simultaneous purification of 6 cell populations and an analyzer by mass cytometry, a technique in full development to analyze simultaneously up to 42 markers.
David Dombrowicz (Team director) : email@example.com
Olivier Molendi-Coste (Technical manager and research engineer) : firstname.lastname@example.org
Laurent Pineau (Research engineer) : email@example.com
ADME-PK – Drug-Design Plateform
The qualitative and quantitative characterization of the effects associated with the administration of a compound to a model animal is the keystone of the drug discovery process. Indeed, this step is essential for estimating a future therapeutic effect and evaluating the risk-benefit ratio of a drug candidate. As such, it is a necessary step in most therapeutic innovation projects, before deciding to hire a candidate for clinical trials. In these experiments conducted in vivo, the variability of the pharmacodynamic response often requires large numbers to deliver significant results.
In a legitimate context of the 3R “Replacement, Reduction and Refinement” which governs the use of animal experimentation, it is essential to use in these experiments only compounds for which we will have previously proven in vitro, and later on a small number of animals, that they reach their site of action at the rate and concentration required to exert their effect.
Consequently, evaluation of ADME parameters (Absorption, Distribution, Metabolism and Elimination) is widely used during target validation, hit-discovery, hit-to-lead optimisation stages. These parameters make it possible to assess the exposure of animals to the compound and to relate it to the importance of the effect and engagement of the target.
Our platform allows to evaluate these parameters rapidly and provides project leaders with the relevant information to select the best compounds for in vivo experiments and to better interpret in vivo data. Moreover, these ADME data will drive the optimisation of the lead structure toward the best possible in vivo performance.
Knowledge and services
Scientifics Managers : Pr. B. Déprez & Dr F. Leroux (firstname.lastname@example.org)
Operational Manager : C. Piveteau (email@example.com)
Integrative Metabolomics and Phenomics AnalytiCs for Translational and Precision Medicine (IMPACT-PM) Platform
UMR 1283 – 8199 Functional (Epi)genomics and Mechanisms of Type 2 diabetes and related diseases
The IMPACT-PM (Integrative Metabolomics and Phenomics AnalytiCs for Translational and Precision Medicine) platform is dedicated to high-resolution mass spectrometry-based metabolomics in biomedical settings. Our mission is to deliver a comprehensive characterisation of the metabolome in various biomedical contexts using high-throughput high-resolution accurate mass workflows, with enhanced coverage and high-confidence annotation for more than two thousand metabolites, lipids and drugs.
IMPACT-PM specialises in profiling and absolute quantification of small molecules in biofluids (plasma, serum, urine, cerebrospinal fluid, faeces), soft tissues, mammalian cells and other complex biological samples, including biologically active microbial metabolites produced by the gut microbes to map the chemical diversity of the compounds in our intestinal pharmacopoeia.
The platform is operated by highly qualified staff covering a range of advanced analytical chemistry and data science approaches.
Our platform is equipped with state-of-the-art high-resolution accurate mass spectrometry (Orbitrap Exploris™ 240 Mass Spectrometer coupled to Vanquish Duo chromatography, Thermo Fisher Scientific).
By integrating mass spectrometry data, chemoinformatics, genomic and metagenomic data, we deliver new knowledge produced within the IMPACT-PM platform.
- High throughput targeted and untargeted metabolomics analyses in biofluids.
- High-confidence annotations based on our in-house library of 2,800+ pure standards.
Knowledge and services
Metabolomics, Microbiomics, High-Resolution Mass Spectrometry
Group Leader and Platform Head : Dr. Marc-Emmanuel DUMAS (firstname.lastname@example.org)
Postdoc, lead for chemometrics: Dr. Francesc PUIG CASTELLVÍ (email@example.com)
Postdoc, lead for standards library and Met ID: Dr. Romina PACHECO TAPIA (firstname.lastname@example.org)